Department of Hematology, Oncology, and Palliative Care, Schwarzwald-Baar Clinic, Academic Teaching Hospital, University of Freiburg, Villingen-Schwenningen, Germany.
Oncologist. 2013;18(8):954-64. doi: 10.1634/theoncologist.2013-0079. Epub 2013 Jul 30.
For patients with advanced indolent non-Hodgkin's lymphoma (NHL) or elderly patients with mantle cell lymphoma (MCL), the recently reported results of the German StiL NHL-1 2003 and the international BRIGHT phase III trials showed that, as first-line treatment, the combination of bendamustine and rituximab is at least as effective as rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone or rituximab/cyclophosphamide/vincristine/prednisone, possibly with a better therapeutic index. Bendamustine is therefore increasingly used in clinical practice. Because bendamustine has been used for many years in Germany and in Switzerland, our institutions have had extensive experience with bendamustine, both as a single agent and in combination with rituximab. In this comprehensive review, we summarize the most important clinical data from phase II/III trials with bendamustine in patients with indolent NHL and MCL, both in the relapsed/refractory setting and in the first-line setting. In addition, this review provides practical advice on how to optimally manage bendamustine therapy in patients with NHL.
对于晚期惰性非霍奇金淋巴瘤（NHL）或老年套细胞淋巴瘤（MCL）患者，最近报道的德国 StiL NHL-1 2003 研究和国际 BRIGHT Ⅲ期试验结果表明，作为一线治疗，苯达莫司汀联合利妥昔单抗与利妥昔单抗/环磷酰胺/多柔比星/长春新碱/泼尼松或利妥昔单抗/环磷酰胺/长春新碱/泼尼松等效，可能具有更好的治疗指数。因此，苯达莫司汀在临床实践中越来越多地被使用。由于苯达莫司汀在德国和瑞士已经使用多年，我们的机构在单药和联合利妥昔单抗治疗惰性 NHL 和 MCL 患者方面积累了丰富的经验。在这篇综述中，我们总结了苯达莫司汀治疗复发/难治性惰性 NHL 和 MCL 患者的 II/III 期临床试验中最重要的临床数据，包括一线治疗。此外，本综述还就如何优化 NHL 患者的苯达莫司汀治疗提供了实用建议。
